KOREA ARLICO PHARM CO.,LTD. Logo

KOREA ARLICO PHARM CO.,LTD.

Manufactures generic drugs and provides CDMO services to a global market.

260660 | KO

Overview

Corporate Details

ISIN(s):
KR7260660006
LEI:
Country:
South Korea
Address:
서울특별시 서초구 바우뫼로27길 7-21 (양재동), 서초구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Korea Arlico Pharm Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's operations are centered on the production and distribution of generic pharmaceuticals, including prescription (ETC) and over-the-counter (OTC) drugs, as well as a specialized Contract Development and Manufacturing Organization (CDMO) business for third-party clients. Its product portfolio addresses a range of therapeutic areas, including circulatory and digestive system disorders, anti-inflammatory analgesics, and hypertension. The company also develops and sells medical devices and active pharmaceutical ingredients. Operating from PIC/S GMP-certified facilities, Korea Arlico Pharm distributes its products in its domestic market and exports to numerous countries globally, positioning itself as a key domestic manufacturer with international reach.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 761.7 KB
2025-06-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 116.0 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 679.2 KB
2025-04-30 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.8 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 17.8 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.1 MB
2025-03-06 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 83.6 KB
2025-02-26 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 5.7 KB
2025-02-26 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 81.1 KB
2025-02-25 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.0 KB
2025-02-12 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.3 KB
2025-02-12 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 9.1 KB
2024-12-17 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 127.6 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB

Automate Your Workflow. Get a real-time feed of all KOREA ARLICO PHARM CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOREA ARLICO PHARM CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOREA ARLICO PHARM CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.